Fatores determinantes no disclosure em Responsabilidade Social Corporativa (RSC): um estudo qualitativo e quantitativo com empresas listadas na Bovespa Communication level and determinant factors of corporative social responsibility disclosure: a qualitative and quantitative study of companies listed in Bovespa

O presente trabalho constitui-se, enquanto uma pesquisa qualitativa e quantitativa, que a partir do levantamento de literatura acerca do processo de disclosure, em responsabilidade social corporativa (RSC) em companhias brasileiras. Realizou levantamento dos relatórios disponibilizados pelas companhias listadas na BOVESPA (Bolsa de Valores do Estado de São Paulo) para um conjunto de 123 empresas, fundamentado pelo referencial da Teoria da Divulgação Voluntária e da Teoria da Legitimidade, aliado à técnica estatística da análise fatorial, buscou identificar o nível de comunicação das informações relacionadas ao desempenho em RSC e prováveis fatores determinantes ao disclosure em responsabilidade social corporativa (RSC) a partir de variáveis independentes do desempenho econômico-financeiro e social (distribuição de riqueza) dessas companhias. Os resultados obtidos no estudo sugerem que a política de disclosure em RSC para as empresas que formaram a amostra demonstrou ser bastante incipiente e altamente vinculada a aspectos de externalidade positiva (marketing social), sendo possível estabelecer uma determinação significante entre o desempenho econômico-financeiro e social com o disclosure em RSC, para as empresas que atuam em atividade regulamentada.<br>The current article is a qualitative and quantitative study based on the literature regarding the corporative social responsibility (CSR) disclosure in Brazilian companies. This research evaluated reports provided by companies listed in BOVESPA (Stock Exchange of the State of São Paulo, Brazil). Based on the Voluntary Disclosure Theory and Legitimacy Theory, 123 companies were evaluated in combination with factor analysis, a statistical technique, in order to identify the level of communication concerning sharing information related to CSR performance and the probable determinant factors to corporative social responsibility (CSR) disclosure using financial economical, and social performance (wealth distribution) as independent variables. The results obtained in the study suggest that the CSR disclosure policy of those companies proved very incipient and highly related to aspects of positive externality (social marketing), and therefore it is possible to establish a strong relationship between economical, financial, and social performance and CSR disclosure for the companies that carry out regulated activities

International Nosocomial Infection Control Consortiu (INICC) report, data summary of 43 countries for 2007-2012. Device-associated module

We report the results of an International Nosocomial Infection Control Consortium (INICC) surveillance study from January 2007-December 2012 in 503 intensive care units (ICUs) in Latin America, Asia, Africa, and Europe. During the 6-year study using the Centers for Disease Control and Prevention's (CDC) U.S. National Healthcare Safety Network (NHSN) definitions for device-associated health care–associated infection (DA-HAI), we collected prospective data from 605,310 patients hospitalized in the INICC's ICUs for an aggregate of 3,338,396 days. Although device utilization in the INICC's ICUs was similar to that reported from ICUs in the U.S. in the CDC's NHSN, rates of device-associated nosocomial infection were higher in the ICUs of the INICC hospitals: the pooled rate of central line–associated bloodstream infection in the INICC's ICUs, 4.9 per 1,000 central line days, is nearly 5-fold higher than the 0.9 per 1,000 central line days reported from comparable U.S. ICUs. The overall rate of ventilator-associated pneumonia was also higher (16.8 vs 1.1 per 1,000 ventilator days) as was the rate of catheter-associated urinary tract infection (5.5 vs 1.3 per 1,000 catheter days). Frequencies of resistance of Pseudomonas isolates to amikacin (42.8% vs 10%) and imipenem (42.4% vs 26.1%) and Klebsiella pneumoniae isolates to ceftazidime (71.2% vs 28.8%) and imipenem (19.6% vs 12.8%) were also higher in the INICC's ICUs compared with the ICUs of the CDC's NHSN